Andere Sprachen Cartesian Therapeutics, Inc.

Aktien

A407YS

US8162123025

RNAC

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.04.2024			% 5 Tage	% 1. Jan.
20.9 ^USD	+0.87%		+20.95%	+1.05%

23.04.	CARTESIAN THERAPEUTICS, INC. : Bewertung von Leerink Partners zum Kaufen erhalten	ZM
14.03.	Cartesian Therapeutics, Inc erhält Mitteilung von Audentes Therapeutics, Inc über Astellas? Beendigung der Lizenz- und Entwicklungsvereinbarung	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting	22.04.
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference	04.04.
Cartesian Therapeutics Announces New Employment Inducement Grants	04.04.
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split	28.03.
Cartesian Therapeutics : Termination of Material Agreement - Form 8-K	14.03.
Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement	14.03.
Cartesian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	07.03.
Cartesian Therapeutics to Participate in Upcoming Investor Conferences	06.03.
Cartesian Therapeutics Announces New Employment Inducement Grant	05.03.
Cartesian Therapeutics, Inc. Announces Resignation of Aymeric Sallin as Member of the Board of Director and Member of Compensation Committee	05.03.
Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland	05.03.
Cartesian Therapeutics, Inc. Establishes New Corporate Headquarters and mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland	05.03.
Cartesian Therapeutics Announces New Employment Inducement Grants	05.02.
Kaskela Law LLC Announces Investigation of Cartesian Therapeutics, Inc. (NASDAQ: RNAC) and Encourages Investors to Contact the Firm	18.01.
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity	08.01.
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis	08.01.
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis	08.01.
Cartesian Therapeutics, Inc.(NasdaqGM:RNAC) dropped from NASDAQ Biotechnology Index	15.12.
Cartesian Therapeutics, Inc. Announces Resignation of Scott D. Myers as Member of the Board, Compensation and Nominating and Corporate Governance Committees	27.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cartesian Therapeutics, Inc.

Aktien

A407YS

US8162123025

RNAC

Andere Sprachen

Filter